Marburg hemorrhagic fever

Summary

Marburg hemorrhagic fever (MONDO:0020500) is a disease and 12 clinical trials. Top therapeutic interventions include galidesivir and avi-7288. A subtype of viral hemorrhagic fever — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 74
• Clinical trials: 12

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		500	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

74 HPO clinical features (Orphanet curated; top 50 by frequency):

HPO ID	Term	Frequency
HP:0001882	Leukopenia	Very frequent (80-99%)
HP:0001888	Lymphopenia	Very frequent (80-99%)
HP:0010702	Increased circulating antibody level	Very frequent (80-99%)
HP:0020071	Viremia	Very frequent (80-99%)
HP:0030005	Capillary leak	Very frequent (80-99%)
HP:0001892	Abnormal bleeding	Frequent (30-79%)
HP:0001923	Reticulocytosis	Frequent (30-79%)
HP:0001945	Fever	Frequent (30-79%)
HP:0002013	Vomiting	Frequent (30-79%)
HP:0002014	Diarrhea	Frequent (30-79%)
HP:0002027	Abdominal pain	Frequent (30-79%)
HP:0002039	Anorexia	Frequent (30-79%)
HP:0002315	Headache	Frequent (30-79%)
HP:0003326	Myalgia	Frequent (30-79%)
HP:0004332	Abnormal lymphocyte morphology	Frequent (30-79%)
HP:0012137	Abnormal number of granulocyte precursors	Frequent (30-79%)
HP:0025143	Chills	Frequent (30-79%)
HP:0030953	Conjunctival hyperemia	Frequent (30-79%)
HP:0032043	Odynophagia	Frequent (30-79%)
HP:0032169	Severe infection	Frequent (30-79%)
HP:0410257	Neutrophilia in presence of infection	Frequent (30-79%)
HP:0002716	Lymphadenopathy	Occasional (5-29%)
HP:0002829	Arthralgia	Occasional (5-29%)
HP:0002900	Hypokalemia	Occasional (5-29%)
HP:0002910	Elevated circulating hepatic transaminase concentration	Occasional (5-29%)
HP:0003073	Hypoalbuminemia	Occasional (5-29%)
HP:0003128	Lactic acidosis	Occasional (5-29%)
HP:0003236	Elevated circulating creatine kinase concentration	Occasional (5-29%)
HP:0003256	Abnormality of the coagulation cascade	Occasional (5-29%)
HP:0003259	Elevated circulating creatinine concentration	Occasional (5-29%)
HP:0003418	Back pain	Occasional (5-29%)
HP:0003645	Prolonged partial thromboplastin time	Occasional (5-29%)
HP:0008151	Prolonged prothrombin time	Occasional (5-29%)
HP:0011029	Internal hemorrhage	Occasional (5-29%)
HP:0011151	Obtundation status	Occasional (5-29%)
HP:0011896	Subconjunctival hemorrhage	Occasional (5-29%)
HP:0012534	Dysesthesia	Occasional (5-29%)
HP:0025085	Bloody diarrhea	Occasional (5-29%)
HP:0030139	Excessive bleeding after a venipuncture	Occasional (5-29%)
HP:0031246	Nonproductive cough	Occasional (5-29%)
HP:0031273	Shock	Occasional (5-29%)
HP:0040186	Maculopapular exanthema	Occasional (5-29%)
HP:0410288	Hyperamylasemia	Occasional (5-29%)
HP:0000083	Renal insufficiency	Occasional (5-29%)
HP:0000718	Aggressive behavior	Occasional (5-29%)
HP:0000967	Petechiae	Occasional (5-29%)
HP:0000978	Bruising susceptibility	Occasional (5-29%)
HP:0000988	Skin rash	Occasional (5-29%)
HP:0001250	Seizure	Occasional (5-29%)
HP:0001254	Lethargy	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	Marburg hemorrhagic fever
Mondo ID	MONDO:0020500
EFO	EFO:0007358
MeSH	D008379
Orphanet	99826
DOID	DOID:4327
ICD-10-CM	A98.3
ICD-11	696598707
NCIT	C84883
SNOMED CT	77503002
UMLS	C0024788
MedGen	9888
GARD	0009444
MedDRA	10026822
Is cancer (heuristic)	no

Also known as: Green monkey disease · Marburg disease · Marburg virus disease · MHF

Disease family

This is a subtype of viral hemorrhagic fever. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › viral hemorrhagic fever › Marburg hemorrhagic fever

Related subtypes (15): Dengue hemorrhagic fever, arenavirus hemorrhagic fever, Ebola hemorrhagic fever, Venezuelan equine encephalitis, Lujo hemorrhagic fever, Bolivian hemorrhagic fever, Venezuelan hemorrhagic fever, Brazilian hemorrhagic fever, Chapare hemorrhagic fever, hantavirus pulmonary syndrome, Rift valley fever, Kyasanur forest disease, Omsk hemorrhagic fever, hemorrhagic fever-renal syndrome, Crimean-Congo hemorrhagic fever

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	10
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06620003	PHASE2	ACTIVE_NOT_RECRUITING	A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
NCT05817422	PHASE2	COMPLETED	Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults
NCT07425821	PHASE1	RECRUITING	A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
NCT00605514	PHASE1	COMPLETED	Ebola and Marburg Virus Vaccines
NCT00997607	PHASE1	COMPLETED	Evaluating an Ebola and a Marburg Vaccine in Uganda
NCT01353040	PHASE1	COMPLETED	Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
NCT01566877	PHASE1	COMPLETED	A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
NCT02891980	PHASE1	COMPLETED	A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
NCT03475056	PHASE1	COMPLETED	cAd3-Marburg Vaccine in Healthy Adults
NCT03800173	PHASE1	COMPLETED	A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
NCT04723602	PHASE1	COMPLETED	Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
NCT06265012	PHASE1	COMPLETED	Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GALIDESIVIR	2	1
AVI-7288	1	1
CHEMBL5287375	0	1